Q2 2025 Embla Medical hf Earnings Call Transcript
Key Points
- Embla Medical hf (OCSE:EMBLA) reported a 7% sales growth in Q2 2025, with 5% being organic, driven by strong performance in the Prosthetics and Neuro Orthotics segment.
- The company achieved a strong EBITDA margin of 21% for the quarter, up from 19% in the first half of 2024, due to robust sales and cost discipline.
- Embla Medical hf has narrowed its full-year guidance to 5% to 6% organic sales growth, reflecting confidence in continued strong performance.
- The acquisition of a majority share in Streifeneder ortho.production is expected to strategically enhance Embla Medical's product offering and market reach.
- The company received recognition from Forbes Magazine for Championing Accessibility and from Iceland's President for Excellence and Global Exports, highlighting its industry leadership.
- Sales in the Bracing & Supports segment declined by 2% in Q2 2025, impacted by lower patient volumes for elective procedures and moderate price pressure.
- The gross profit margin decreased to 62% from 64% in the same quarter last year, affected by softer sales and US tariffs.
- The acquisition of Streifeneder ortho.production is expected to be slightly dilutive to margins in the short term.
- Embla Medical hf's free cash flow decreased to $12 million in Q2 2025 from $18 million in the same period last year, due to increased CapEx and net working capital.
- The company faces uncertainty regarding the impact of US tariffs and competitive bidding changes on its financial performance.
Welcome to Embla Medical conference call for Q2 2025. Today's call is being recorded. (Operator Instructions)
I would now like to introduce President and CEO, Sveinn Solvason; and CFO, Arna Sveinsdottir. Please begin your presentation.
Thank you very much, and good morning, and welcome to the Embla Medical conference call where we will review the second quarter of 2025. I'm Sveinn Solvason, President and CEO of Embla Medical. Joining me on today's call is our Chief Financial Officer, Arna Sveinsdottir; and Embla Medical's Head of Investor Relations, Klaus Sindahl. The presentation should take approximately 15 minutes, after which there will be an opportunity to ask questions during a Q&A session.
If we could go to the next slide, please. Sales in the second quarter amounted to $232 million, representing 7% reported growth of which 5% was organic. Both were strong in the Prosthetics and Neuro Orthotics segment, mainly driven by the continued momentum in EMEA and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
